Vertex Pharmaceuticals, Inc. (VRTX)
547.59
-0.46
(-0.08%)
USD |
NASDAQ |
Aug 24, 16:00
547.98
+0.39
(+0.07%)
After-Hours: 04:35
Vertex Pharmaceuticals Net Income (Quarterly) : 1.100B for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.100B |
| March 31, 2026 | 1.031B |
| December 31, 2025 | 1.191B |
| September 30, 2025 | 1.083B |
| June 30, 2025 | 1.033B |
| March 31, 2025 | 646.30M |
| December 31, 2024 | 913.00M |
| September 30, 2024 | 1.045B |
| June 30, 2024 | -3.594B |
| March 31, 2024 | 1.100B |
| December 31, 2023 | 968.80M |
| September 30, 2023 | 1.035B |
| June 30, 2023 | 915.70M |
| March 31, 2023 | 699.80M |
| December 31, 2022 | 818.90M |
| September 30, 2022 | 930.50M |
| June 30, 2022 | 810.50M |
| March 31, 2022 | 762.10M |
| December 31, 2021 | 770.10M |
| September 30, 2021 | 851.93M |
| June 30, 2021 | 66.92M |
| March 31, 2021 | 653.14M |
| December 31, 2020 | 604.19M |
| September 30, 2020 | 667.43M |
| June 30, 2020 | 837.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 602.75M |
| December 31, 2019 | 583.23M |
| September 30, 2019 | 57.52M |
| June 30, 2019 | 267.43M |
| March 31, 2019 | 268.63M |
| December 31, 2018 | 1.525B |
| September 30, 2018 | 128.44M |
| June 30, 2018 | 206.18M |
| March 31, 2018 | 227.20M |
| December 31, 2017 | 102.10M |
| September 30, 2017 | -291.27M |
| June 30, 2017 | 31.15M |
| March 31, 2017 | 249.14M |
| December 31, 2016 | 27.76M |
| September 30, 2016 | -39.54M |
| June 30, 2016 | -36.15M |
| March 31, 2016 | -36.10M |
| December 31, 2015 | -76.45M |
| September 30, 2015 | -93.82M |
| June 30, 2015 | -220.99M |
| March 31, 2015 | -198.70M |
| December 31, 2014 | -180.64M |
| September 30, 2014 | -170.00M |
| June 30, 2014 | -159.38M |
| March 31, 2014 | -232.46M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| Sionna Therapeutics, Inc. | -29.89M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.344B |
| Total Expenses (Quarterly) | 2.244B |
| EPS Diluted (Quarterly) | 4.310 |
| Enterprise Value | 132.85B |
| Gross Profit Margin (Quarterly) | 85.37% |
| Profit Margin (Quarterly) | 32.89% |
| Earnings Yield | 3.14% |
| Operating Earnings Yield | 3.58% |
| Normalized Earnings Yield | 3.225 |